

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with e-mail dated September 1, 2013
1. Community Medical Center, Inc.	3. License number 25-18361-01 is amended in its entirety to read as follows:
2. 2827 Fort Missoula Road Missoula, Montana 59804	4. Expiration date May 31, 2013
	5. Docket No. 030-14921 Reference No. 25-29220-01 (030-37118)

- | | | |
|---|----------------------------------|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license |
| A. Any byproduct material permitted by 10 CFR 35.100 | A. Any | A. As needed |
| B. Any byproduct material permitted by 10 CFR 35.200 | B. Any | B. As needed |
| C. Any byproduct material permitted by 10 CFR 35.300 | C. Any | C. 500 millicuries |
| D. Any byproduct materials permitted by 10 CFR 31.11 | D. Prepackage Kits | D. 50 millicuries |

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any use permitted by 10 CFR 35.300.
- D. In vitro studies.

CONDITIONS

- 10. A. Licensed material may be used or stored only at the licensee's facility located at 2827 Fort Missoula Road, Missoula, Montana.
- B. Licensed material permitted by 10 CFR 35.200 (except gases), may be used for imaging and localization studies at temporary job sites of the licensee's anywhere in the United States where the U.S. Nuclear Regulatory Commission maintains jurisdiction for regulating the use of licensed material, including areas of exclusive Federal jurisdiction within Agreement States.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
25-18361-01

Docket or Reference Number
030-14921 Reference No. 25-29220-01 (030-37118)

Amendment No. 27

If the jurisdiction status of a Federal facility within an Agreement State is unknown, the licensee should contact the federal agency controlling the job site in question to determine whether the proposed job site is an area of exclusive Federal jurisdiction. Authorization for use of radioactive materials at job sites in Agreement States not under exclusive Federal jurisdiction shall be obtained from the appropriate state regulatory agency.

11. The Radiation Safety Officer for this license is James H. Brewer, Ph.D.
12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user and/or authorized nuclear pharmacist in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for the material and medical uses indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Newton B. Coutinho, M.D.	35.200
William J. Birck, M.D.	35.100; 35.200; 31.11; oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries only for imaging and localization studies
Thomas A. Layne, M.D.	35.100; 35.200; 31.11; oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries only for imaging and localization studies
Kyle L. Dale, M.D.	35.100; 35.200; oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries
Joel A. Brake, M.D.	35.100; 35.200
Anthony R. D'Amico, M.D.	35.100; 35.200
Adam J. Benson, M.D.	35.100; 35.200; 35.300
Wayne L. Davis, M.D.	35.100; 35.200; 35.300; 31.11
Sarsfield Patrick Dougherty, M.D.	35.100; 35.200; 35.300; 31.11
Paul H. Eikens, M.D.	35.100; 35.200; 35.300; 31.11
Mark W. Elliott, M.D.	35.100; 35.200; 35.300; 31.11
Daniel M. Fruechte, M.D.	35.100; 35.200; 35.300; 31.11
James E. McKay, Jr., M.D.	35.100; 35.200; 35.300; 31.11
Michael A. Stewart, M.D.	35.100; 35.200; 35.300; 31.11
Michael R. Tryhus, M.D.	35.100; 35.200; 35.300; 31.11

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
25-18361-01Docket or Reference Number
030-14921 Reference No. 25-29220-01 (030-37118)

Amendment No. 27

Authorized UsersMaterial and Use

Roy W. "Chip" Zimmer, III, M.D.

35.100; 35.200; 35.300; 31.11

David Bauer, M.D.

35.100; 35.200; oral administration of sodium iodide I-131

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing financial assurance for decommissioning.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Facsimile dated August 16, 2002 (ML023040685)
B. Application dated December 31, 2002 (ML030300316)
C. Facsimile dated May 16, 2003 (ML080580287)
D. Letter dated February 11, 2008 (ML080520608)
E. E-mails dated February 25 and 27, 2008 (ML080580278)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

/RA/

Date: September 4, 2013By: _____
Michelle M. Hammond, M.Sc., Health Physicist
Nuclear Materials Safety Branch B
Region IV
Arlington, Texas 76011-4511